ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Tango Therapeutics (TNGX) pipeline and stated timing

Name in SEC filings: Tango Therapeutics, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
vopimetostat + RAS(ON) inhibitors/data readoutOtherOctober 23-27, 202610-Q ·
TNG456Topline/data readoutStage not statedsecond half of 202610-Q ·
vopimetostatTopline/data readoutStage not stated202610-Q ·

Source: ORION, orionbiotechai.com/company/TNGX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/TNGX

Nearest upcoming stated timing: vopimetostat + RAS(ON) inhibitors · Topline/data readout · October 23-27, 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

vopimetostat + RAS(ON) inhibitors

Matched

Topline/data readoutOctober 23-27, 2026

Stage: OtherSEC filing · “Phase 1/2”

Public float: $528,400,000 · as of · SEC filing

We plan to share data from the Phase 1/2 trial of the combination of vopimetostat plus RAS(ON) inhibitors at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain from October 23-27, 2026.

10-Q · Filed · Last checked

Source details

Accession 0001193125-26-343424

Alert me · Calendar: same stage and window-end month (2026-10)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
TNG456Clinical resultssecond half of 2026
“We anticipate providing initial clinical data from this trial in the second half of 2026.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

vopimetostatClinical results2026
“disclose clinical data in the lung cancer cohort of the vopimetostat monotherapy clinical trial in 2026”

Filed · 10-Q

Still within period

As of Oct 19, 2026

vopimetostat + RAS(ON) inhibitorsClinical resultsOctober 23-27, 2026
“We plan to share data from the Phase 1/2 trial of the combination of vopimetostat plus RAS(ON) inhibitors at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain from October 23-27, 2026.”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

TNG456Clinical results 2026
“Release initial TNG456 glioblastoma data 2H 2026”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

vopimetostatClinical results2H 2026
“Disclose vopimetostat lung cancer monotherapy data in 2H 2026”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

vopimetostat + RAS(ON) inhibitorsClinical results2H 2026
“Present 2/3L PDAC vopimetostat + RAS(ON) inhibitors combination data at a scientific conference 2H 2026”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

TNG456Clinical results2026
“We anticipate providing initial clinical data from this trial in 2026.”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

vopimetostatClinical results2026
“we anticipate providing a safety and efficacy update in 2026.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

vopimetostatClinical results2026
“we anticipate providing a safety and efficacy update in 2026.”

Filed · 10-K

Still within period

As of Oct 19, 2026

vopimetostatClinical results2026
“we anticipate providing a safety and efficacy update in 2026.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch TNGX

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for TNGX. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See TNGX in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.1H means January–June and 2H means July–December of the stated year, unless the company uses a different fiscal year.